Rochester Institute of Technology

RIT Scholar Works
Theses
4-3-2020

Applying Systems Pharmacology to the Treatment of Chronic
Illness Using Novel Scoring and Translational Methods
Spencer Richman
scr6045@rit.edu

Follow this and additional works at: https://scholarworks.rit.edu/theses

Recommended Citation
Richman, Spencer, "Applying Systems Pharmacology to the Treatment of Chronic Illness Using Novel
Scoring and Translational Methods" (2020). Thesis. Rochester Institute of Technology. Accessed from

This Thesis is brought to you for free and open access by RIT Scholar Works. It has been accepted for inclusion in
Theses by an authorized administrator of RIT Scholar Works. For more information, please contact
ritscholarworks@rit.edu.

Applying Systems Pharmacology to the Treatment of Chronic
Illness Using Novel Scoring and Translational Methods

Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of
Master of Science in Bioinformatics

Spencer Richman*†
Advisory Committee:
Gordon Broderick†‡
Matthew Morris*†
Gary Skuse*†

*

Gosnell School of Life Sciences, Rochester Institute of Technology
†Center for Clinical Systems Biology, Rochester General Hospital
‡Department of Biomedical Engineering, Rochester Institute of Technology

Rochester Institute of Technology
College of Science
Thomas H. Gosnell School of Life Sciences
Master of Science in Bioinformatics
04/03/2020

II
Dedication
This work is dedicated to the millions that have suffered and will continue to suffer from chronic
disease.
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Abstract
Chronic illnesses are poorly understood diseases that are often highly resistant to treatment. The
prevalence and severity of these illnesses necessitates new methods for treatment development that
diverge from the paradigm of one drug, one illness. Instead, multidrug interventions that utilize
repurposable, previously approved drugs could be far more advantageous. In order to support this,
a novel scoring framework and accompanying set of tools, collectively termed DrugAble, have
been developed. DrugAble scores proposed, model-based treatment target solutions by analyzing
drug-target interaction data and addressing the network complexity of these solutions.
Actionability scores that summarize the likelihood of a proposed target set constituting a
pharmacologically accessible path to remission are generated. Additionally, DrugAble proposes
combinations of repurposable drugs that can potentially be used in tandem to achieve remission.
Here, DrugAble is demonstrated on molecular target solutions supporting an escape from Myalgic
Encephalomyelitis / Chronic Fatigue Syndrome, a debilitating illness that affects up to 2.5 million
Americans alone. DrugAble effectively discriminates between theoretical target sets and those that
are clinically actionable using available drugs while simultaneously accounting for drug-target
interactions and off-target effects of these drugs. This framework constitutes the necessary first
steps to designing more effective treatments for chronic illnesses, with the ultimate goal of
reducing the failure rate of clinical trials and the financial burden on both drug developers and
patients. Most importantly, it opens new and more immediately accessible paths toward achieving
remission and full recovery for those suffering from chronic illnesses.
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Introduction
Chronic diseases are an increasingly studied though still incompletely understood set of illnesses
with continual impacts on society. While exact definitions vary, chronic disease differs from
traditional disease in that it is characterized by a long-term presence of symptoms, often greater
than three months1. These diseases are usually multi-symptomatic and lead to a variety of health
complications in affected persons1. According to the National Health Council, greater than 75%
of all healthcare costs are due to chronic disease, and as of 2007, this was a total of 1.3 trillion U.S.
dollars annually. It is projected that by 2023, these costs will reach upwards of 4.3 trillion dollars1,2.
The economic costs speak nothing of the toll that these diseases take on the lives of those affected.
Chronic diseases are often debilitating, and greatly reduce the quality of life of those suffering
from such diseases. An increasing amount of multidisciplinary research is being conducted on how
best to prevent, treat, and cure chronic diseases.
Over the past two decades, understanding of chronic disease has moved beyond hypotheses
that attribute disease to single causes and that present as homogeneous phenotypes. It is
increasingly understood that many chronic diseases are in fact highly heterogeneous in both
etiology and presentation despite umbrella medical definitions3–6. This new understanding of
chronic disease has led to an increased need for systems-level approaches to analysis and treatment
of these illnesses. The field of systems biology arose from a need to analyze biological questions
from a scope that far exceeds traditional analysis approaches. Viewing disease from the
perspective of many co-interacting molecular and enzymatic pathways is a more robust and often
more realistic perspective on disease7,8. Furthermore, because many chronic diseases lack a single
identifiable cause, they are difficult to analyze using traditional methods. Systems biology allows
researchers to analyze chronic disease from a wide angle and to consider multiple possible causes
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of disease. When combined with other modern approaches to rapid analysis and treatment, systems
biology becomes a powerful clinical tool9,10. However, modeling the full complexity of biological
systems is computationally and temporally expensive, and thus the resolution of these models is
often limited. By reducing the complexity of biological models into qualitative-- or discrete-values and decisions, the size of the model can be increased even under relatively limited
computational capacity. Instead of models containing dozens or even hundreds of parameters,
models can be generated with as few as three parameters (a ternary model), each representing a
directional, specific interaction between two system components11. For example, the effects of the
addition of a drug to a system can be modeled as having one of three effects on each component
of the system-- no interaction, inhibition, or activation. Using such models means that, even in the
absence of kinetic data and numerous measurements that would otherwise be required, the ultimate
state of the system can be calculated. This has the inherent advantage of being able to design larger
models, but it comes at the cost of resolution. In reality, biological models are continuous
functions. Nevertheless, discrete representations of biological systems can lead to robust and
valuable results.
Such discrete models have been applied to solving and understanding hypothesized “steady
states” responsible for chronic disease12,13. These steady states represent stable, homeostatic
“basins” in the topology of a model, which, regardless of the beneficence of this state, the
biological system maintains12. Movement into a new steady state can be triggered by perturbations
that propagate through the system. In other words, these perturbations can trigger a movement
from a stable, healthy state to a stable disease state-- chronic disease12,13. Discrete methods for
analyzing the existence of and movement to these steady states work particularly well because
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they do not require any knowledge of a system’s kinetics. It does not matter when the system
reaches the steady state, it only matters why it reaches such a state12.
The development of these discrete logic models has enabled computation of minimally
invasive drug interventions for the treatment of chronic disease. A Minimal Intervention Set (MIS)
is defined by the least number of perturbations needed in order to induce a transition between
steady states in a model12. In a clinical reality, this represents the least number of therapies that
will induce the required changes. In the context of this work, an MIS constitutes a set of molecular
target-action pairs. Mathematically, there are often multiple ways in which the system may come
to rest in a given steady state, and multiple steady states in the system. Through the use of Monte
Carlo methodologies and constraint satisfaction solvers, the behavior of a given system can be
determined from any starting state, and the likelihood of the system following a certain path can
be determined. This is further described in Craddock, et al., 2018. These same methodologies are
applied in the development of treatments. By simulating the immediate effect of a treatment-upregulation or downregulation of a component-- the system is then allowed to evolve towards a
new steady state12,13. By repeating these simulations many times, the likelihood of a given
treatment succeeding can be calculated. However, the bulk of existing work in this has focused on
the identification of treatment targets regardless of how effectively or how specifically they might
be modulated using known pharmaceutical compounds. Many if not most of these idealized
treatments may translate poorly if at all to the clinical space as evidenced by the high failure rate
of phase II clinical trials.
General approach
The current ethos underlying treatment design focuses on single-drug interventions that
target a specific molecular process. Unfortunately, such treatments are often ineffective when
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treating chronic disease because of the multifaceted causes of these diseases. As a result, clinical
trials for treatments of many chronic illnesses fail14–16. The exceptionally long and costly nature
of clinical trials17 means that there is significant motivation to avoid dedicating resources to
difficult-to-treat illnesses. In recent years, a new focus on the repurposability of drugs has arisen.
Thousands of FDA approved drugs, originally for the treatment of one or more relevant conditions,
may also be valuable for treating newly identified and newly understood illnesses18,19. This
approach could be a significant boon to both pharmaceutical companies and sufferers of chronic
disease, as time-to-market may be greatly reduced by implementing repurposing strategies.
Nevertheless, there remains a need to both reduce the failure rate of clinical trials and to design
new, efficacious treatments to chronic illnesses.
To address the failure of single-drug interventions, a paradigm shift is required. Multidrug
interventions, where drugs work synergistically with one another may be more effective than
individual drugs alone. This paradigm has already begun to take hold in some areas of medicine,
especially for the treatment of HIV infection and various cancers. A similar paradigm, known as
polypharmacology, has attempted to replace the single drug, single target philosophy with a “single
drug, multiple target” philosophy20. However, this area of pharmacology is not amenable to
repurposing of drugs and still does not address all of the challenges that the use of multiple drugs
attempts to overcome. In complex chronic diseases, multidrug treatments may prove to be
exceptionally effective.
There are important considerations that must be made when designing multidrug treatment
courses. The treatments must be as minimally invasive as possible and the number of drugs, their
frequency of dosage, and their side-effects should be as few as possible in order to reduce strain
on the patient. While dosing parameters are outside the scope of this project, there remains a
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challenge to effective treatment design that computational methods can help resolve. Off-target
drug interactions can greatly complicate a treatment course through unintended effects to the
system that were not known during the model generation phase.
Methods to detect off-target interactions have been widely employed in the field of drug
discovery and design. Often, a variety of in silico procedures are used to identify these interactions.
Work by Yera et al., 2014 demonstrated a novel methodology combining natural language
processing of patient packet information and computational analysis of the 2D and 3D structures
of drug molecules using adapted established methods21. This data fusion technique produces a
probabilistic model for how likely two drugs are to share molecular targets. The methodology was
validated using the Structural Pharmacology Database and the chEMBL database. In 2017,
Chartier et al., using a combination of Protein Data Bank, PISCES, and DrugBank data, performed
binding-site similarity analyses for 400 drugs and 7,895 different proteins. Chartier identified
multiple drug-repurposing candidates as well as a large set of interactions that may explain the
side-effects of certain drugs22. These works successfully demonstrate valid means for the
computational prediction of off-target drug interactions. While these applications have
traditionally been applied to drug discovery and design, similar methods are justifiably applicable
to treatment design as well. Because predictive methods based on physical interactions and
structural models are computationally intensive and limited to proteins with solved structures,
other approaches may be preferable. The application of drug-target information for multidrug
treatment design has precedent. Torres et al, 2016, analyzed pairs of drugs in DrugBank and
developed scoring methods for predicting synergistic effects between pairs of drugs while also
accounting for off-target effects23. However, their work focused specifically on pairs of drugs and
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on developing signed networks of drug-target effects without focus on scoring differing solutions,
repurposing drugs, or predicting treatment combinations.
In order to address the above-mentioned translational gaps, the current work is focused on
aligning model-predicted molecular and cellular targets with pharmaceutical agents already in
clinical practice as well as known compounds biochemically catalogued but not yet approved for
use. To meet this goal, quantitative criteria have been developed to assess the relative ranking of
treatment target sets on the basis of their off-target effects, the interchangeability of compounds,
expected downstream effects and the consensus among models in the robustness of predicted
response. This theory has been implemented in the form of a computational framework known as
DrugAble, which mines existing knowledge-bases for drug-target interaction data, links these data
to targets in a provided model, ranks the solutions to the model, and translates high-scoring
solutions into pharmaceutical interventions using repurposable compounds.
Methods
Drug Identification
Effective implementation of the proposed scoring methodology requires maximal data on
drug-target interactions. There are many web databases with drug-target information, including
DrugBank, PharmGKB, and others. However, because effective data fusion from these sources,
which do not utilize a standard format nor standard naming conventions, is difficult an alternative
was sought. Instead, an API interface to the Elsevier Pathway Studio Service, dubbed DTQuery,
is implemented. The Pathway Studio database contains a massive amount of drug-target
information collected from literature mining of 3.5 million full texts and 24 million PubMed
abstract, as well as putative interactions imported from Reaxys Medicinal Chemistry. DTQuery
accepts input as a JSON file describing the modulations required for each target in all possible
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MIS candidates and a file containing target names, their alternative names, and identifiers. Using
this information, a series of queries is performed to the web database. Query 1, provided in a
pseudo-SQL form, searches for all small-molecule drugs that modulate any of the provided targets.
Query 2 then iterates over the results of the first query, returning all known targets of each
identified small-molecule drug. This provides the necessary information on off-target effects.
Every drug-target interaction that is identified is written to a local flat file.
Query 1: Drugs that Modulate Each Target

Query 2: Find all Off-Target Effects

Candidate Solution Scoring
The scoring of input solutions is a critical component of the DrugAble pipeline. A novel scoring
function, henceforth known as Actionability (α), is designed to be a quantitative measure of the
beneficence of a solution. Each of the five component scores summarize key information about
both the solution and available drugs that may satisfy the parameters of the solution. Additionally,
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two tuning parameters are defined that allow for weighted adjustment of the contribution of
cardinality and the antagonist ratio, described below. The composite nature of Actionability
allows fine-tuning to account for both the complexity of the solutions and the nature of the drugs
used to achieve the solutions.
In the following equations, a model is defined as a set of logical vectors each representing
a solution to the discrete logic model being analyzed. Iverson bracket notation is used for logical
operations, where conditions within square brackets evaluate to 1 if true and 0 if false. Finally, set
cardinality is defined by the vertical line enclosure (||).
The first component of α is cardinality (C). Cardinality is defined in this instance as the
sum of non-zero elements of the polarity vector that defines a candidate solution to a model. The
formal definition for the cardinality of a vector s is provided below in Equation (1) :
Equation 1:

where n is the number of targets in the model, si is the polarity of the target at index i, and 0 is a
neutral polarity. It is generally best to promote candidate solutions with minimal cardinality.
Candidate solutions with greater cardinalities will likely require a greater number of drugs in order
to achieve a remissive state, which introduces a greater risk of destabilizing off-target effects and
negative side effects for patients.
The second component score, the antagonist ratio (V) is defined as the ratio of antagonist
actions to agonist actions in a candidate solution. It is generally accepted in pharmacology that it
is easier to downregulate a drug target than to upregulate one []. The antagonist ratio has been
incorporated in order to promote candidate solutions that require less upregulation of targets, and
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thus are more likely to have available drugs. The formal definition for a candidate solution s is
provided below in Equation (2):
Equation 2:

where n is the number of targets to be modulated, si is the polarity of the target at index i, p is the
sum of antagonist actions, q is the sum of agonist actions, 1 arbitrarily represents an antagonist
action and 2 arbitrarily represents an agonist action. Maximizing the antagonist ratio is ideal.
The third component score, repurposability (R), is a measure of the likelihood that a
candidate solution can be translated into a true pharmaceutical intervention. It is a function of the
number of drugs that exist for each target. The greater the number of available drugs, the more
likely that a valid drug combination can be generated. Repurposability also serves as a filtering
score. Any candidate solution with no available drugs automatically receives an R score of zero,
which by design floors α to zero. The formal definition for the repurposability of a candidate
solution s is provided in Equation (3):
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Equation 3:

where n is the number of targets to be modulated and ŝi is the set of all drugs that act with the
correct polarity on si. Solutions with higher R are likely to have more varied combinations of
drugs available when generating interventions when compared with lower R values.
The fourth component of α, the target score (T) effectively measures the mean number of
targets a given intervention developed from a candidate solution is expected to have. This measure
is agnostic to both whether interactions are on or off-target and to the polarity of the interactions.
The formal definition for the target score of a candidate solution s is provided in Equation (4):
Equation 4:

where n is the number of targets to be modulated and Ki is the set of sums of interactions for every
drug that also interacts with target i. Thus, T(s) is the geometric mean of the minimum possible
number of target interactions across all targets in s. Solutions with a lower T are more likely to
yield drug interventions with fewer off-target effects, and so it follows that minimizing T is ideal.
α incorporates the four component scores as well as two tuning parameters, τ and γ, which
allow for adjusting the weights of V and C respectively. Because V and C are derived from the
structure of the MIS in contrast to the data-driven R and T scores, the ability to adjust their
contributions to the final score can be useful. Higher values of τ and γ place scoring emphasis on

11
ideal MIS structure. Being able to adjust τ and γ independently from one another allows for even
finer rank-tuning. The formal definition of α for a given candidate solution s is provided in
Equation (5):
Equation 5:

where R, V, C, and T are the same as defined in Equations (1:5).
While individual component scores can be useful when gauging the viability of a candidate
solution, a single summary measure is far wieldier. In addition, the ability to weight α with the
provided tuning parameters means that implementations of the scoring system can be fine-tuned
for what is considered most desirable in each analysis. In any circumstance, a more maximal α for
a solution is considered best. Final actionability scores are normalized between 0 and 1 for ease of
interpretation. It should be noted that neither α nor any of its component scores can be directly
compared with the same scores from a non-structurally identical model, nor across differing drugtarget datasets. These scores are only valid in the context of the specific models and datasets used
to generate the scores. There is opportunity for future research into developing a normalized score
that can compare scores across different datasets and models.
Intervention Generation
The final major component of the DrugAble pipeline translates high-scoring candidate solutions
into proposed clinical interventions. These proposed interventions must satisfy two restrictions.
First, they must act upon, with correct polarity, every target prescribed to be modulated by the
candidate solution. Second, they must use no more drugs than the cardinality of the candidate
solution. Interventions that meet these requirements are considered valid.
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Exhaustive generation of interventions is best-formulated as an NP-hard constraintsatisfaction problem24. In order to overcome the challenges brought by this, a heuristic approach
using search-space reduction and ranking has been devised. Search-space reduction to identify
viable drugs is performed based on three requirements. First, the drug must modulate at least one
prescribed target in the candidate solution with correct polarity. Second, the drug must not
modulate any other target in the solution with incorrect polarity. Third, any drug whose mean
number of off-target effects is greater than one standard deviation from the mean number of offtarget effects for all drugs is excluded. Ranking is similarly performed in two steps. In the first
ranking operation, drugs with a higher number of on-target effects are promoted. In the second
ranking operation, drugs with more off-target effects are demoted. If at this point there are any
drugs whose number on-target effects is equal to the cardinality of the candidate solution, a rare
single-drug intervention has been identified. Most often, this is not the case.
Multi-drug interventions are then generated using an iterative combinatorial algorithm.
First, all combinations of size 2:m from drugs n, formulated as n Choose 2:m, are generated, where
m is no larger than the cardinality of the candidate solution. From this, a large random sample of
combinations are selected. Second, all combinations whose total number of on-target effects are
less than the cardinality of the candidate solution are discarded. Third, combinations containing
redundant matches, such as two or more drugs modulating all of the same targets, are culled. The
resulting set of valid drug combinations is then output. Use of a heuristic “filter-rank-filter”
methodology allows for the generation of valid interventions in far less compute-time than a
constraint-satisfaction solver or exhaustive guess-and-check strategies.
Modeling Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
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Myalgic Encephalomyelitis / Chronic Fatigue Syndrome is a severe chronic illness that affects
millions of individuals across the world. Over a million in the United States alone suffer from
illnesses that can be categorized as ME / CFS . ME / CFS, while highly complex, is generally
categorized by long periods of severe bodily fatigue rendering sufferers unable to function
effectively. In addition to fatigue, sufferers often experience debilitating whole-body pains and
mental deficits. ME / CFS, affects upwards of one-percent of the world’s population, of which the
overwhelming majority are women25. Both the etiology and presentation of ME / CFS are poorly
understood, and in fact may comprise a set of similar but distinct conditions. Nevertheless, ME /
CFS is increasingly understood in part to be the result of immune dysregulation, likely induced by
viral infection26,27.
Morris et al., 2019 developed a regulatory model of ME / CFS based on 28 molecular
targets, 214 regulatory interactions, and 17 immune markers measured from a cohort of 88 females
with diagnosed ME / CFS28 . These targets are outlined in Table 1. These 28 targets form a
highly interconnected regulatory network between the immune and endocrine systems, as well as
the HPA and HPG axes. Sex hormones exercise significant control over the immune system,
especially in females29, and this multi-axis network is believed to become dysregulated following
severe viral infection, such as by the Epstein-Barr virus30.
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Target

Class

Function

Norepinephrine

Hormone

Stress response modulation

Estrogen

Hormone

Development and regulation of
female reproductive system

Dopamine

Hormone

Motor control, hormone control

Cortisol

Hormone

Blood sugar modulation, immune
system suppression

Luteinizing Hormone

Hormone

Testosterone production (males),
ovulation (females)

Follicle-stimulating hormone

Hormone

Body growth and development,
pubertal maturation, reproductive
modulation

Gonadotropin releasing hormone 1

Hormone

FSH modulation, LH modulation

Corticotropin releasing hormone

Hormone

ACTH synthesis modulation

Progesterone

Hormone

Menstrual cycle, pregnancy,
embryogenesis (females),
testosterone production (males)

Stress

Physiological response

Survival instinct promotion

Natural Killer Cell

Cell

Response to viral infection

B-Cell

Cell

Antibody & cytokine secretion,
antigen recognition

Interferon Gamma

Cytokine

Macrophage activation, MHC
induction, response to viral
infection

Tumor Necrosis Factor

Cytokine

Cell proliferation and
differentiation, cell death

IL1A

Cytokine

Inflammatory response, Th2 cell
activation

IL1B

Cytokine

Inflammatory response

IL2

Cytokine

Immune response modulation
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IL4

Cytokine

Th2 cell induction

IL5

Cytokine

B-cell growth stimulation

IL6

Cytokine

Multifunctional, pro/antiinflammatory response

C-X-C motif chemokine ligand 8
(CXCL8)

Chemokine

pro-inflammatory response,
neutrophil recruitment

IL10

Cytokine

B-cell proliferation, Th1 inhibition

IL12

Cytokine

Th1 cell induction

IL13

Cytokine

Allergic immune response

IL15

Cytokine

Anti-apoptotic response

IL17A

Cytokine

Proinflammatory response, NFKB
& MAPK regulation

IL23

Cytokine

Proinflammatory response, Th17
mediator

Table 1: Parameters of the Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Model
Twenty-Eight hormones, cytokines, chemokines, and immune cells form the interaction network model of ME / CFS.
All drugs identified by DTQuery directly act upon one or more of these targets. However, no drugs were identified
that directly target NK-Cell or stress.

Currently, no effective interventions, pharmaceutical or otherwise, exist for the treatment
of ME / CFS31. In order to address this issue, MIS candidate solutions from five selected models
of ME / CFS were pooled. These MIS candidates serve here as data for the proof-of-concept
implementation of DrugAble. Preprocessed solutions were fed to DTQuery in order to identify
relevant drug-target interactions, and this dataset of interactions was used to perform actionability
scoring and intervention generation for this solution set.
Results
In total, 44,845 drug-target interactions (19,013 agonist, 16,367 antagonist) were identified
using target-action pairs described by 2,515 MIS candidates. This includes traditional smallmolecules drugs, lead compounds, monoclonal antibodies, and query contaminants. Query
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contaminants include elemental dimers, nonspecific hits such as DMSO, and other nonpharmaceutical compounds that were identified during querying. The effect of contaminants on
dataset quality is demonstrated in Figure 1A, where the Ca2+ ion has 632 annotated interactions,
but is not an actual pharmaceutical. In figure 1B, ambiguous interactions were removed from the
dataset, preserving only interactions annotated as “positive” or “negative.” This filtered Ca2+ and
other contaminants from the dataset, tightening the distribution of counts of targets per drug
significantly. In Figure 1C, the distribution of drugs can be seen per in-model target. Candidate
solutions where targets with high opportunity for repurposability (R score) are more likely to
receive a higher actionability score, though this is also dependent on the other component scores
of Actionability. In this dataset, TNF, IL6, CXCL8, and IL1B appear to be exceptionally
druggable. As expected, most drugs identified for these targets act as inhibitors. Oppositely, neither
NK-cell nor stress are druggable. NK-cells, because of their central and essential role in the innate
immune system, would almost never be intentionally targeted by a pharmaceutical. Stress, on the
other hand, is difficult to target when it is treated as a single condition. Stress is itself multifaceted
and not a single molecular target. It would therefore be rare for a drug to be annotated as directly
targeting stress. Figure 1C also facets the total number of drugs identified per target by whether
those drugs inhibit or promote the target. Across all targets, there are 1.8x more drugs that inhibit
these targets than there are that promote it, justifying the inclusion of the antagonist ratio as a
component score of actionability.
The propensities for each target in the ME / CFS model to be inhibited or promoted can be
seen in Figure 2. Interestingly, NK-cell and stress, the two targets for which no drugs were
identified, are never modulated in any of the candidate solutions. ACTH, IL2, IL4, and IL5 are
also never modulated. No single target is modulated in every candidate solution, suggesting the
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presence of multiple subgraphs that lead to the same outcome. In Figure 3, the number of solutions
by cardinality is divided per model. While model 3 produced the majority of total solutions (2005),
it produced almost exclusively high-cardinality solutions. Combined, 97 percent of solutions had
a cardinality of five or greater. Only 2.3 percent of solutions were of cardinality four or less, with
none below a cardinality of three. The lack of low-cardinality solutions reinforces the highly
complex nature of ME / CFS, and demonstrates the necessity of including cardinality as a
component score of actionability.
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Figure 1: Drugs Identified by DTQuery
A summary of the drugs and compounds identified by querying the Elsevier Biological Knowledgebase.
In (A), the distribution of all 44,845 relations is presented, including non-specific annotated interactions
such as interactions labeled as “unknown.” The median number of interactions is 1.0 interaction / drug.
In (B) ambiguous interactions have been removed, leaving only interactions annotated as “positive” or
“negative.” Additionally, interactions with targets outside of the model have been removed. In (C) a
breakdown of the polarity of interactions by target is provided. Note that NK-cell and stress are truly
zero.
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Figure 2: Upregulation and
Downregulation of Targets
The majority of targets are inhibited
more often than they are promoted,
with the notable exceptions of GNRH1,
IL1A, IL12, IL15, and IL17A. IL2,
IL4, IL5, NK-cell, stress, and ACTH
are never modulated.
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Figure 3: Density of Actionability Scores
A) The distribution of all actionability scores is presented. B) The actionability scores are separated by
cardinality, from 2 to 5. Actionability is normalized from 0.0 to 1.00, where 1.00 is the most actionable
solution. The blue highlighted area is a best-fit curve to describe the distribution of scores.
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Figure 4: Pairwise Correlations of Component Scores
A) Pairwise scatterplots for each component score of actionability verses each other component, as well as the total
actionability score. Diagonals are the distribution of each score, and the upper triangle shows the Pearson correlation
for the corresponding cells. B) The same correlations shown in the upper triangle of A, but color-coded by magnitude.
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Figure 5: The Effects of Tau and Gamma Tuning Parameters on Actionability
A) Negative values of tau invert the antagonist ratio metric, instead prioritizing solutions with high
agonist ratios. Positive values increase the weight of antagonist ratios on actionability. B) Negative values
of gamma should not be used, as they prioritize high-cardinality solutions. Positive values increase the
weight of cardinality on actionability. For both tau and gamma, values between 1 and 4 are recommended.
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Actionability is not a statistical measure. It does not attempt to assign a probability of success or
failure to a solution, only to rank solutions by their ability to be translated into pharmaceutical
interventions in comparison to all other solutions available, using known drug-target interactions
and knowledge about the structure of the solution. A normalized actionability score of 0.9 for a
given candidate solution does not mean that this solution has a 90 percent chance of successfully
being translated or succeeding as a pharmaceutical intervention. Rather, an α of 0.9 says that a
solution is 90 percent more likely to be a good solution, as defined by the standards of an ideal
solution, than the lowest-ranking solution.
Nevertheless, it is important to verify that actionability is a meaningful measure of the
ideality of a solution. Before the implementation of actionability, the only measure for assessing
the goodness of a candidate solution was cardinality. Cardinality, while an important metric-hence its inclusion in actionability-- does not provide enough information alone to accurately score
MIS candidates. As figure 4 demonstrates, no component score alone is able to provide the same
level of discrimination as actionability is in total. While the antagonist ratio has a strongly positive
correlation (0.9) with actionability, this correlation is somewhat spurious. Despite a clear upward
trend in actionability with increasing antagonist ratio, which is expected as per the function of the
antagonist ratio in calculating actionability, the possible values of actionability vary greatly at each
level of antagonist ratio. The highest antagonist ratio predicts normalized actionabilities ranging
from 0.215 to 1.0, a very large range. The distribution of each score is also worth noting.
Actionability is exceptionally bimodal, with a very high concentration of very low-actionability
scores. The bimodal nature of this distribution is likely caused by the filtering effects of the
component scores, which rather harshly cause solutions with even one or two non-ideal component
scores to drop out. The antagonist ratio distribution is also bimodal, with values concentrated at
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either end. This suggests that it is common for solutions to have either many antagonized targets
or many agonized targets, and far less often a comparable number of both, but it is important to
note that this can vary greatly between models and illnesses. The moderate negative correlation (0.4) between repurposability and target score is also to be expected, because with an increasing
number of available drugs (I.e., a higher repurposability), the target score is likely to increase due
to an increasing number of off-target effects from those drugs.
The strictness of actionability can be adjusted with the tuning parameters τ and γ. These
two parameters act as exponential scaling factors for the antagonist ratio and cardinality
respectively. The effect of varying levels of τ and γ on the final actionability score can be seen in
Figure 5. In Figure 5A, the distribution of actionability scores at τ values between -6 and +6 are
shown. Any value of τ less than one increases the strictness of actionability greatly. The bimodal
distribution of actionability seen in positive values of τ disappears. For this dataset, any value of τ
below -2 is largely uninformative because most scores become effectively zero. Increasingly
positive values of τ also impart strictness on actionability, though this effect is less extreme than
negative values. As τ increases from 1, the bimodal distribution in this dataset is preserved, but is
shifted into a narrower range toward the lower end of actionability scores. The behavior of γ
(Figure 5B) is distinctly different from that of τ. Negative γ values have a much less drastic effect
on the distribution of actionability scores, though increasingly negative values do lead to a slightly
greater density of mid-level scores. Increasingly positive γ values have a similar but lesspronounced effect on the distribution that increasingly negative values of τ do. In practice, in
datasets with a high number of small-molecule drugs, a higher τ will cause greater separation in
actionability between candidate solutions with high antagonist ratio and those with low ratios. This
may be preferable because small-molecule drugs tend to be antagonists. In the same scenario, a
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high γ will penalize candidate solutions with a high likelihood of generating interventions that
have many off-target interactions. This may be preferable because it will indirectly penalize the
use of promiscuous small-molecule drugs. Conversely, if a dataset is rich in agonist drugs, or a
model is sparse in candidate solutions with antagonist actions, reducing or even inverting the
weighting of these scores can be beneficial. Combined, these two parameters can be used to tune
actionability so that it remains flexible under different assumptions of the ideality of candidate
solutions.
The generation of proposed pharmaceutical interventions is the final major function of
DrugAble. It is also the most computationally demanding. In order to avoid the complexity and
pitfalls of implementing a constraint satisfaction solver to identify combinations, a filter-rank-filter
methodology, described above in the methods section, was implemented. The top ten candidate
solutions were selected for translation to proposed interventions based on their actionability scores.
For each of the ten candidate solutions, all possible interventions of two and three drugs were
generated. Because the generation of combinations is performed iteratively down the supplied list
of drugs, the resulting combinations are implicitly sorted by the least number of off-target effects
and highest number of on-target effects. For each of the top ten solutions ranked by actionability,
the top 20,000 combinations were checked for validity. Table 2 shows the target-action pairs for
the ten highest-ranking solutions, and Table 3 shows the breakdown of valid combinations for
those. Tables 4 and 5 are offered in contrast, showing the same data but for the 10 lowest-ranking
solutions. Table 5 shows the top-ranking interventions for each of the 10 highest-ranking solutions.
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Actionability

IL1B

IL16

1
1
1
0
1
0
0
1
0
0

1
1
1
1
1
1
1
1
1
1

1.00
0.98
0.98
0.97
0.96
0.95
0.93
0.91
0.90
0.90

CXCL8

IL10

1
1
0
1
0
1
0
0
0
1

1
0
1
1
0
0
1
1
0
1

TNF
1
1
1
1
1
1
1
1
1
1

B-Cell
0
0
0
0
0
0
0
1
0
1

Luteinizing
Hormone
0
1
0
0
1
1
0
0
1
0

Table 2: Best Solutions by Actionability
Each of the best ten solutions, ranked by actionability. A 1 represents an antagonistic action, a 0 represents
no action, and a 2 represents an agonistic action (none present).
Actionability

valid

M=2

M=3

Mean OT

1.00

483

57

426

69.6

0.98

88

6

82

62.4

0.98

2254

173

2081

10.1

0.97

2363

171

2191

12.4

0.96

131

27

104

15.6

0.95

135

27

108

17.5

0.93

3000

1310

1690

6.9

0.90

158

21

137

6.9

0.90

105

1

104

21.0

Actionability

0.010
0.010
0.010
0.008
0.007
0.003
0.003
0.002
0.000
0.000

IL1B

0
0
0
1
0
0
0
0
0
0

Table 3: Interventions Generated for
Top Solutions
A breakdown of valid interventions
generated for each of the top ten solutions,
ranked by actionability. M=2 refers to
interventions of size 2, and M=3 refers to
interventions of size 3. Mean OT is the
mean number of off-target effects across
all generated interventions.

IL15

IL1A

IL12

IL17A

IFNG

B-Cell

0
0
2
2
2
0
0
2
2
2

2
0
0
2
0
2
2
0
2
0

0
2
0
2
0
2
2
0
0
2

2
2
2
0
2
2
2
2
2
2

0
0
0
0
0
0
1
0
0
0

0
0
2
0
0
0
0
2
0
0

Cortisol

1
1
0
0
1
1
0
0
1
1

GNRH1

2
2
1
2
2
2
2
1
2
2

Luteinizing
Hormone

0
0
0
0
0
0
0
2
0
0

Table 4: Worst Solutions by Actionability
Each of the worst ten solutions, ranked by actionability. A 1 represents an antagonistic action, a 2 an agonist
action, and a 0 represents no action.
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Actionability

Drug 1

Drug 1 Targets

Drug 2

Drug 2 Targets

Off-Targets

1.00

Rosmarinic acid

IL1B,I L16,TNF,
CXCL8

IC14

Il6, IL10

12

...

...

...

Oxprenolol

IL10

14

...

...

...

norcantharidin

IL10, TNf

33

...

...

...

eplerenone

CXCL8, IL10

21

0.98

Rosmarinic acid

IL1B,IL16,TNF,
CXCL8

Levonorgestrel

Luteinizing Hormone

22

...

...

...

Substance P Antibody

Luteinizing Hormone

10

...

...

...

Galantide

Luteinizing Hormone

12

0.98

Lipid A
Derivatives

IL1B, IL6, TNF

IL12 Antibody

IL10

1

...

...

...

Taurolidine

IL10

1

...

Exosurf Neonatal

IL1B, IL6, TNF

IL12 Antibody

IL10

1

...

...

....

Taurolidine

IL10

1

0.97

Pulegone

IL16, CXCL8, TNF

IL12 Antibody

IL10

1

...

...

...

Taurolidine

IL10

1

...

Ammonium
Acetate

IL16, CXCL8, TNF

IL12 Antibody

IL10

1

...

...

...

Taurolidine

IL10

1

0.96

Lipid A
Derivatives

IL1B, CXCL8, TNF

Substance P Antibody

Luteinizing Hormone

0

...

Exosurf Neonatal

IL1B, CXCL8, TNF

...

...

0

Solution 1

Solution 2

Solution 3

Solution 4

Solution 5

Table 5: Proposed Interventions
A subset of the generated, predicted interventions for the first five solutions. Ellipses indicate that the cell is unchanged from
the cell directly above.
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Discussion
DrugAble implements flexible quantitative measures that allow for the ranking of idealized
candidate solutions to chronic illnesses. The actionability summary measure accounts for both
known drug-target interactions and the complexity of candidate solutions. Importantly,
actionability can be tuned to weigh its component scores differently. This means that users can
define, to a degree, what defines an actionable solution. This is important because no two illnesses,
nor the drug datasets used to examine these illnesses, are the same. While actionability by default
discourages solutions with high numbers of agonistic requirements, it is not infeasible that a
researcher may have a drug-target dataset rich in agonistic drugs. In this case, lowering or even
reversing this weighting may be desirable. For ME / CFS targets and the accompanying drug
dataset mined by DTQuery, agonistic actions were often unsatisfiable or undesirable. This is
evidenced by the total lack of agonist actions in the top ten highest-scoring solutions, and the heavy
presence of agonist actions in the lowest scoring solutions, seen in Tables 2 and 4. While the
actionability scoring was tuned to intentionally lower the rank of agonist actions, this was clearly
justified based on the inability to develop any valid interventions for the lowest-ranking solutions.
Most importantly, actionability is a marked improvement over cardinality alone, the previous
metric used to judge the viability of a solution. As can be seen in Figure 3B, low-cardinality
solutions do not necessarily represent highly actionable ones. The range of actionability scores for
each value of cardinality is often large. If solutions are ranked on cardinality alone, many poorly
clinically actionable solutions may rise to the top. Thus, the use of actionability is necessary in
order to filter out these cases.
Proposed interventions generated by DrugAble need to be examined critically. Table 5
shows the top interventions for each of the top ten solutions. Solution 1, intervention 5 is
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suggesting the use of an IL12 antibody to target IL10, even though it stands to reason that an IL12
antibody would act directly on IL12. Theoretically, this drug should have been filtered during
search-space reduction because IL12 was not a prescribed target for this solution but is present in
the model. However, upon examination of the drug-target database, “interleukin 12 antibody” was
not annotated as modulating IL12. The first drug proposed by all interventions for Solution 5 is
“lipid A derivatives.” Lipid A in this case refers to the lipid component of lipopolysaccharide
endotoxins common to gram negative bacteria32. These are being examined as potential adjuvants
in vaccines because of their effect on immune modulators33. Rosmarinic acid, present in all of the
top interventions for both Solutions 1 and 2, has gained recent attention for its potential ability to
combat neurodegenerative diseases such as Alzheimers34, but remains unverified as a useful
pharmaceutical compound. Pulegone is a known carcinogen35. Oxprenolol and eplerenone are both
anti-hypertensives. These drugs are commonly known as blood-thinners. Coagulation and related
processes are known to be functions of the immune system, regulated by cytokines36,37. IC14 is a
clinical trial-withdrawn CD14 antibody shown to inhibit TNF, IL6, and IL10, originally intended
for the treatment of Amyotrophic Lateral Sclerosis (ALS)38. Seletalisib is an investigational P13K
inhibitor being examined for the treatment of immune inflammatory diseases39. Taurolidine is an
antimicrobial compound also being examined for the treatment of cancers40, though the
mechanisms for this are varied, not fully understood, and possibly hepatotoxic40,41, despite the low
number of annotated interactions. There are various other suggested drugs, many of which are
monoclonal antibodies and other anti-cancer drugs. Most of these chemotherapeutics act through
cytotoxic mechanisms, which are not ideal for treatment of non-cancers. These findings further
reinforce the need for robust drug-target datasets free from contaminating interactions or drugs
known to have undesired effects or mechanisms of action.
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Using the number of off-target effects as a ranking for proposed interventions should be
done with caution. These numbers will be as accurate as the database given to DrugAble. Any
intervention with an exceptionally low number of off-target interactions, especially those with 0,
warrants further analysis because it is rare that a drug is truly without off-target effects. The level
of error in intervention generation is tolerable for two reasons. Firstly, it is often the case that
multiple interventions are generated for a single solution, allowing experts to filter out incorrect
combinations that may slip through. Furthermore, no proposed intervention would ever be
implemented in a clinical trial without thorough examination by pharmacologists. DrugAble is not
attempting to circumvent the need for expert examination, but rather to provide these same experts
with tools to guide their work.
There are areas of improvement for DrugAble. Firstly, while drug-target interactions are
accounted for by the actionability score, drug-drug interactions are not considered during the
intervention generation phase. Future implementations of DrugAble may benefit from utilizing
such knowledge when available, so as to avoid suggesting pharmaceutical interventions with
known, adverse drug-drug interactions. Secondly, DrugAble may benefit from more
straightforward tuning of actionability. The effects of τ and γ as tuning parameters are difficult to
visualize, and there are currently no tuning parameters implemented for the repurposability or
target scores. Thirdly, DrugAble is highly sensitive to poor data quality. Because it has no choice
but to trust the drug-target information it is provided with, spurious results can occur when datasets
have not been well-curated. Improvement to the specificity of queries made to DTQuery may
improve mined dataset quality, but in any case, it is important to ensure that DrugAble is provided
with robust datasets and that results are examined critically. Fifthly, while the filter-rank-filter
intervention generation method is a clever approach to a complex problem, there is potential that
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it will miss valid pharmaceutical interventions. It is also by far the slowest step in the DrugAble
pipeline. Improving the speed and accuracy of intervention generation is therefore important.
Finally, actionability scores are relative. It is not currently possible to compare actionability scores
across models of disease with differing targets and drug-target datasets. If a method to generalize
actionability scores across models and drug-target datasets were developed, it would become
possible to assess the relative complexity of different models against one another. It would also be
possible to assess the robustness of different drug-target datasets. Improving upon DrugAble in
these ways would only enhance its usefulness and accuracy.
Despite the many areas for improvement, the current implementation of DrugAble is a
marked improvement over current methods to design and assess multidrug interventions, which
are few. Data and text mining methods for detecting off-target interactions have been previously
applied by researchers such as Yera, but this data has not to our knowledge been applied toward
the development of multidrug interventions. Computational prediction of drug-target effects is a
major area of research in pharmacology21–23,42,43, but predicted and putative effects are most-often
used to guide traditional drug-development approaches. These new methods support the move
away from traditional drug-development approaches and towards modern approaches that may
prove to be more robust in treating complex illnesses.
An additional component score has been developed in order to further improve
actionability, referred to as the inter-model adjusted confidence score (Ma). Ma is only
implemented when multiple models, utilizing the same targets, are available to an analysis and
have generated solutions. Ma accounts for the possibility that a given candidate solution may be
generated by multiple models, and for the varying robustness and efficiency of those models.
Robustness and efficiency are two measures generated simultaneously with each candidate
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solution. Robustness (r) is the number of times that an MIS candidate succeeds in achieving a
steady-state transition under a given number of simulations and efficiency (m) is the number of
transitions required to achieve the goal steady-state. A detailed explanation of both can be found
in Sedghamiz et al., 2019. The formal definition of Ma for a given candidate solution s is provided
in Equation (6):
Equation 6:

where S is the set of all models containing s, M(r) is the median robustness of the models in S, and
M(m) is the median efficiency of the models in S. When multiple models are present, maximizing
Ma is ideal. However, when only one model is used in the analysis, or the analysis is not based on
model-derived solutions, Ma is defaulted to 1 and thus has no effect on the final scoring. Ma will
allow actionability to account for the variability in the tuning between models, an important step
towards a more generalizable and robust version of actionability.
While the applicability of DrugAble is here demonstrated on chronic illness, specifically
ME / CFS, there is no reason that it cannot be applied to a wide range of other illnesses, both
chronic and acute. Furthermore, while used here on outputs from Bio-ModelChecker, this is not a
strict requirement. So long as inputs are formatted in the way that DrugAble expects them, data
from a variety of sources can be used. Rather than inputting an MIS candidate, proposed sets of
target-action pairs can be given to DrugAble just as any MIS candidate from Bio-ModelChecker
would be. Finally, while DTQuery currently only supports access to Elsevier’s proprietary
biological knowledgebase, any drug-target dataset can be used so long as it is formatted as a drugtarget-action triplicate table. The flexibility in the implementation of DrugAble is important
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because it allows researchers using any number of disease-model development methods and with
virtually any drug-target dataset to also utilize DrugAble.
Conclusions
The prevalence, severity, and stubbornness of chronic diseases necessitates innovative methods
for treatment discovery and design. The long-standing pharmacological paradigm of singledisease, single-drug interventions is both ill-founded and ineffectual for the treatment of chronic
illnesses. In order to shift this paradigm, methods that support the development of both multi-drug
interventions and the use of repurposable drugs are necessary. DrugAble is a promising new
avenue toward the ranking of competing target-action sets and multidrug therapy design that
attempts to address these issues. Its ability to effectively discriminate between theoretical solutions
and those that are clinically actionable based solely on the network-structure of the target sets and
drug-target interaction data can speed up treatment design significantly. By proposing
computationally valid pharmaceutical combinations, researchers can be guided toward the use of
repurposable drugs instead of developing new ones, a costly and time-consuming procedure. By
reducing the barriers to multidrug treatment design and implementation, new paths towards total
remission of ME / CFS and a variety of other chronic illnesses have become available.
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